Home › Funds › Vivo Capital, LLC › AVBP
Vivo Capital, LLC position in AVBP
ARRIVENT BIOPHARMA INC · Health Care
Vivo Capital, LLC reported holding 1,787,104 shares of AVBP (ARRIVENT BIOPHARMA INC) in its Q3 2026 13F filing — a position valued at US$54.1M, representing 6.14% of its reported portfolio and ranking #4 among its reported holdings. Vivo Capital, LLC has disclosed AVBP holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Vivo Capital, LLC's AVBP position evolved
Vivo Capital, LLC first disclosed a stake in AVBP in Q1 2026 at 885,916 shares (US$20.4M). The position peaked in Q2 2026 at 1,682,097 shares, worth US$58.4M. Across 3 filings, Vivo Capital, LLC increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,787,104 shares valued at US$54.1M — an increase of 105,007 shares quarter over quarter.. Notable position changes include a 90% increase in Q2 2026 (shares fell 13% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 885.92K | $20.44M | New |
| Q2 2026 | 1.68M | $58.44M | Add |
| Q3 2026 | 1.79M | $54.11M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AVBP and 13F data
AVBP (ARRIVENT BIOPHARMA INC) is a Health Care company. 56 other funds we track also report a position in AVBP — the largest reported positions include MONTANOVA CAPITAL, LLC (US$156.9M), INFINITUM ASSET MANAGEMENT, LLC (US$154.2M), Hillhouse Capital (HHLR Advisors) (US$136.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AVBP
- MONTANOVA CAPITAL, LLC 4.52M sh · $156.87M · Q2 2026
- INFINITUM ASSET MANAGEMENT, LLC 4.44M sh · $154.19M · Q2 2026
- Hillhouse Capital (HHLR Advisors) 3.93M sh · $136.50M · Q2 2026
- ORBIMED ADVISORS LLC 3.03M sh · $105.17M · Q2 2026
- Octagon Capital Advisors LP 1.97M sh · $68.47M · Q2 2026
- Sofinnova Investments, Inc. 1.70M sh · $58.95M · Q2 2026
- Novo Holdings A/S 1.50M sh · $52.11M · Q2 2026
- General Catalyst Group Management, LLC 1.49M sh · $51.93M · Q2 2026
- Logos Global Management LP 1.00M sh · $34.74M · Q2 2026
- HSG Holding Ltd 663.31K sh · $20.08M · Q3 2026
- Foresite Capital Management VI LLC 301.34K sh · $10.47M · Q2 2026
- Seven Fleet Capital Management LP 246.61K sh · $8.57M · Q2 2026
More on Vivo Capital, LLC
FAQ
How long has Vivo Capital, LLC held AVBP?
Vivo Capital, LLC has disclosed AVBP holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Vivo Capital, LLC's current position in AVBP?
As of Q3 2026, Vivo Capital, LLC holds 1.79M shares of AVBP (ARRIVENT BIOPHARMA INC), valued at $54.11M, representing 6.14% of its reported portfolio and ranking #4.
Has Vivo Capital, LLC been buying or selling AVBP?
In the latest 13F filing (Q3 2026), Vivo Capital, LLC increased its position in AVBP. The position peaked in Q2 2026 at 1.68M shares.
Which other funds hold AVBP?
Other major institutional holders of AVBP include MONTANOVA CAPITAL, LLC, INFINITUM ASSET MANAGEMENT, LLC, Hillhouse Capital (HHLR Advisors), among 56 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.